


Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the above-identified application.

Listing of Claims

Claims 1-20 are cancelled.

21 (Currently Amended). A compound which is 8-chloro-3-pentyl-3,7-dihydro-1*H*-purine- 2,6-dione:



a pharmaceutically acceptable salt ~~or solvate~~ thereof.

22 (Previously Presented). A compound according to claim 21, where the compound is 8-chloro-3-pentyl-3,7-dihydro-1*H*-purine- 2,6-dione.

23 (Previously Presented). A pharmaceutical formulation, which comprises a compound according to claim 21, and one or more physiologically acceptable diluents, excipients or carriers.

24 (Currently Amended). A method for treatment of ~~a lipid metabolism disorder or disease~~, hyperlipidaemia, hyperlipoproteinaemia, hypercholesteraemia, hypertriglyceridaemia, mixed dyslipidaemia or diabetic dyslipidaemia, which comprises administering a therapeutically effective amount of a compound of claim 21 to a human ~~or animal~~ subject.

25 (Cancelled).

26 (New). A method for treatment of coronary artery disease or atherosclerosis, which comprises administering a therapeutically effective amount of a compound of claim 21 to a human subject.